Stock Opinions by Jason Snipe, CIO, Odyssey Capital Advisors

COMMENT

The quarter last week was solid with earnings and sales both us and a solid guide. But export controls are a concern as are third-party selling via China. There is definitely continued demand, but that demand is slowing.

BUY

Revenues are up $6.8 billion in a strong quarter. Gross bookings were up and are converting cash flow. He remains bullish.

BUY

Skyrizi continues to work.

BUY

There's a lot riding on the print (earnings after the close) today. Shares are down 17% since the DeepSeek news. Now, we're hearing export controls. However, the hyperscalers have not changed their capex spending on AI ; DeepSeek had no real impact, including Microsoft and Meta and Amazon. We need to hear from NVDA $38 billion in revenue and guide $2-3 billion over and above, and hear about insatiable demand. He expects a strong print.

BUY

They beat top and bottom, with a positive surprise in same-store sales. Good. The pro segment continues to growth with wider margins. And we're entering a strong seasonal period.

BUY

He likes big pharma with AbbVie his favourite name. Pipelines are starting to fill, and if rates hold and R&D gets cheaper, these stocks will continue to work.

BUY ON WEAKNESS

Is down nearly 20% in the last 3 weeks. With 21% revenue growth and 18% EPS growth, they continue to monetize AI.

BUY

They're monetizing their AI tools.

COMMENT
Reuters/ISOS poll says 53% of American feel the economy is on the wrong track vs. 43% in Jan. 24-26

Breadth of the rally has expanded this year, but it has slowed. Trump's tariffs are a negotiating tool, but the market has seen 16% earnings growth vs. 12% expected, and a 77% beat rate in earnings. The market has digested last week's hotter than expected inflation numbers. The market is a mixed bag now, but he's overall more bullish.

COMMENT

They didn't guide high enough. Meta is no longer 20% of their business, but 15% while Microsoft and Oracle make up more of their business.

WAIT

It hit a new low. 69% of their homes cost under $400,000, so they appeal to first-time homebuyers. This is wait and see.

BUY

It's the best in medical devices. Tailwinds are the aging demographic and rising elective surgeries coming back.

BUY

It leads the Mag 7 this week. The quarter was fine. In response to tariffs, they are moving some supply chains to Indonesia and Indian, away from China. Chinese phones are taking market share, but we've gotten past this news. Apple services were +14% this quarter and beat the top and bottom with an 8% growth rate. He will ride it up.

BUY

The last quarter was mostly in line. The new platform will take time to transition. It's trading off, because that last quarter was not a blow-out. But cybersecurity stocks will continue to work.

BUY

They lead in cloud network solutions, sales +20%, EPS +31%. Innovation in AI will only lift this stock.

Showing 1 to 15 of 261 entries